⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493581 | 0.91 | — | — | |
| SCHEMBL834366 | 0.84 | — | — | |
| SCHEMBL1267181 | 0.83 | — | — | |
| SCHEMBL4317503 | 0.73 | — | — | |
| SCHEMBL4318976 | 0.68 | — | — | |
| SCHEMBL24236 | 0.67 | — | — | |
| SCHEMBL4314494 | 0.67 | — | — | |
| SCHEMBL4317631 | 0.65 | — | — | |
| SCHEMBL4318392 | 0.65 | — | — | |
| SCHEMBL13728745 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092764-A1 | KINASE INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-03-21 | — | — | US | claimed |
| US-20240092765-A1 | METHODS OF INHIBITING KINASES | INSILICO MEDICINE IP LIMITED (HK) | 2024-03-21 | — | — | US | claimed |
| US-11795160-B2 | Kinase inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-10-24 | — | — | US | claimed |
| US-11739078-B2 | Methods of inhibiting kinases | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-29 | — | — | US | claimed |
| EP-3927700-A1 | KINASE INHIBITORS | Insilico Medicine IP Limited (HK) | 2021-12-29 | — | — | EP | claimed |
| US-20200270234-A1 | KINASE INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2020-08-27 | — | — | US | claimed |
| US-20200270231-A1 | METHODS OF INHIBITING KINASES | INSILICO MEDICINE IP LIMITED (HK) | 2020-08-27 | — | — | US | claimed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | claimed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | claimed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | claimed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | claimed |
| EP-1401841-A1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2004-03-31 | — | — | EP | claimed |
| WO-2003000699-A1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO[4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2003-01-03 | — | — | WO | claimed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-0832898-A2 | Substituted amino acid derivatives | BAYER AG (DE) | 1998-04-01 | — | — | EP | claimed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | claimed |